With PROTAC 5 in hand, we first determined AKR1C3 inhibition activity and its ability to ameliorate the survival of 22Rv1 prostate cancer cells that express high levels of AKR1C37. The gene discussed is AKR1C3; the disease is Familial prostate cancer.